Sclerostin is a bioactive glycoprotein primarily secreted by osteocytes that plays a crucial role in regulating bone formation and remodeling. It acts as an antagonist of the Wnt/β-catenin signaling pathway, binding to LRP5/6 co-receptors and inhibiting osteoblast activity, thereby reducing bone formation. Because of this regulatory function, sclerostin helps maintain skeletal homeostasis but also contributes to bone loss when present in excess, as seen in conditions like osteoporosis. Its bioactivity has made it a significant therapeutic target—most notably in the development of sclerostin-inhibiting monoclonal antibodies, which enhance bone formation and improve bone mineral density.
Biomedica’s Bioactive Sclerostin ELISA Kit was highlighted in a recent study investigating the association of total and bioactive serum Sclerostin levels with bone metabolism in type 2 diabetes mellitus (T2DM). Click below for the full publications, where you can find the abstracts and key findings!
If you have any questions about this Bioactive Sclerostin ELISA assay kit or any of our other offerings, contact Eagle Biosciences here.